Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can scientists unlock the secrets of breathing muscle failure in severe COPD?

NCT ID NCT06935825

Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study investigates why breathing muscles weaken in people with end-stage COPD, a severe lung disease. Researchers will measure muscle function using non-invasive tests like ultrasound and EMG, and analyze muscle tissue samples taken during lung transplant surgery. The goal is to understand the underlying processes and how treatments like non-invasive ventilation affect these muscles. Sixty adults on the lung transplant waiting list will participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could uncover why respiratory muscles weaken in severe COPD and how treatments like ventilation or transplant affect them, potentially guiding better therapies.
What could go wrong
This is an early exploratory study with only 60 participants, so findings may not apply broadly. It observes rather than tests a treatment, so no direct benefit for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

COPD patients on the lung transplantation waiting list

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

In order to be eligible to participate in this study, a participant must meet all of the following criteria: * Age \> 18 years old * Severe COPD defined as COPD GOLD stage III or IV (FEV1 \< 50% of predicted; FEV1/FVC ratio \< 70%, no significant reversibility, smoking history of at least 10 pack-years). * Being on the lung transplant waiting list * Being able to understand the patient information and provide written informed consent for participation in the study A potential participant who meets any of the following criteria will be excluded from participation in this study: * Patients suffering from acute conditions at the time of inclusion or LTx * Patients using more than 20 mg of morphine, or an equivalent, or more than 20 mg oxazepam, or an equivalent, at the time of inclusion or LTx

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Radboud University Medical Center

    NOT_YET_RECRUITING

    Nijmegen, Netherlands

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.